Compare EVH & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | BBNX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.0M | 493.1M |
| IPO Year | 2015 | N/A |
| Metric | EVH | BBNX |
|---|---|---|
| Price | $6.20 | $16.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $7.93 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 2.3M | 943.7K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,957,000.00 | N/A |
| Revenue This Year | $33.89 | $34.90 |
| Revenue Next Year | $15.84 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $8.80 |
| 52 Week High | $11.81 | $32.71 |
| Indicator | EVH | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 72.28 | 64.29 |
| Support Level | $3.67 | $16.02 |
| Resistance Level | $8.30 | $32.52 |
| Average True Range (ATR) | 0.37 | 1.10 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 95.61 | 81.77 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.